DAY 4 - Wednesday, June 29, 2011

Greetings from the American Diabetes Association's 71^st Scientific Sessions

The editorial staff of Medical Economics brings you daily coverage of breaking news, the latest research findings, and reports of interest to the readers of Medical Economics, Drug Topics, Formulary, and Contemporary OB/GYN.

Our four-day coverage of this year's American Diabetes Association's 71st Scientific Sessions includes the results of major clinical trials and ongoing news and information of interest to clinicians who treat type 1 and 2 diabetes.

BREAKING NEWS

Anti-VEGF antibody injections result in sustained improvement in vision in diabetic macular edema

An anti-vascular endothelial growth factor (VEGF) antibody fragment given intraocularly significantly and rapidly improves vision in patients with diabetes and macular degeneration. The improvements are sustained up to 2 years, said David S Boyer, MD.
» MORE

CLINICAL TRIALS

Continuous SQ exenatide lowers HbA1c, weight with better tolerability

Continuous subcutaneous delivery of exenatide using an investigational infusion device resulted in substantial decreases in glycosylated hemoglobin (HbA_1c) in patients with type 2 diabetes without the nausea associated with twice-daily exenatide injections, reported investigators in an extension of a phase II study. » MORE

Protégé: Teplizumab fails in type 1 diabetes prevention; endpoint may have been poor choice

Nicole Sherry, MD

Teplizumab, an anti-CD3 monoclonal antibody designed to preserve beta cell function and decrease insulin needs in patients with recent-onset type 1 diabetes, was no better than placebo at meeting a composite endpoint in the phase III international Protégé trial.» MORE

NEW RESEARCH

Calcium channel blocker/angiotensin receptor blocker combination helps patients with diabetes hit goal blood pressure after failed monotherapy

In patients with type 2 diabetes and uncontrolled hypertension while on antihypertensive monotherapy, more than one half had their blood pressure controlled after switching to a fixed-dose combination of amlodipine/olmesartan, said Shawna D Nesbitt, MD.» MORE

Glargine plus exenatide does not increase hypoglycemia in type 2 diabetes

The combination of insulin glargine and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide was associated with significant reductions in glycosylated hemoglobin (HbA_1c) without increasing hypoglycemia in patients with poorly controlled type 2 diabetes.» MORE

Effect of metformin, statin use on prostate cancer incidence may be enhanced by one another

Metformin and statins seem to have a synergistic effect on reducing prostate cancer risk, according to Donna Lehman, PhD. While metformin alone increases prostate cancer risk and statins alone decrease risk, with combined use of the two together, “we saw an even greater drop in the hazard ratio [HR] for prostate cancer” than with statins alone, she said.» MORE

PATIENT MANAGEMENT

Self-monitoring in ACCORD confirms lower glucose, more hypoglycemia with intensive control

A review of self-monitored blood glucose data downloaded from monitors used by participants in the ACCORD trial shows that patients assigned to the intensive-glycemic-control arm complied with frequent glucose monitoring but also had significantly more episodes of hypoglycemia than patients who followed standard diabetes care.» MORE

Knowledge of diabetes is high, but this knowledge is not being translated into action

A large survey of American households reveals generally high knowledge of diabetes and its risk factors, yet few people willing to change behavior to improve their health. Further, predictors for progression to type 2 diabetes are easy to identify from respondents' reports.» MORE

Medical Economics is pleased to share this ADA conference coverage with the readers of:

From the conference floor

We welcome your feedback!
Please send your comments to:
Medical Economics editorial staff
[email protected]